Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Coronary Artery Disease, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Colchicine, Myocardial Injury, Inflammation, Myocardial Infarction, No Reflow
Eligibility Criteria
Inclusion Criteria: Chronic Coronary Syndrome (CCS) participants referred for PCI. Acute Coronary Syndrome (ACS) participants who are medically treated or undergoing revascularization for non-culprit lesions will be included if their troponin I and hs-CRP returned back to normal baseline Exclusion Criteria: Acute Coronary Syndrome (ACS) participants. Chronic kidney disease (glomerular filltration rate <30 ml/ min). Participants with history of cirrhosis. Participants on systemic immunosuppressive or corticosteroid therapy. Active malignancy or infection. Elevated troponin I.
Sites / Locations
- Helwan University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Colchicine
Placebo
0.5 mg colchicine tablets twice daily 72 to 48 hours before planned PCI
Matching placebo